What is keytruda's age range for treatment?

What age group does Keytruda treat?

Keytruda is approved for patients 18 and older across most indications, including advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. A smaller set of pediatric approvals exist for relapsed or refractory classical Hodgkin lymphoma, microsatellite instability-high solid tumors, and Merkel cell carcinoma in patients as young as 6 months. The label lists no upper age limit, and dosing is the same for adults and eligible children.

When is Keytruda used in children?

Doctors prescribe Keytruda for certain hard-to-treat cancers in infants and children when other treatments have failed. The youngest approved age is 6 months for the three indications noted above. Clinical trials that supported these approvals included patients from 6 months to 17 years. Outside these specific cancers, Keytruda remains investigational or unapproved in pediatric populations.

How does Keytruda dosing differ by age?

The recommended dose is 200 mg every three weeks for adults and for children weighing 40 kg or more. Children under 40 kg receive 2 mg per kg every three weeks. No dose adjustment is required for older adults, though kidney or liver function is monitored more closely in patients over 65.

Does age affect Keytruda safety?

Side-effect profiles are similar across adult age groups, but older patients experience higher rates of immune-related adverse events such as colitis and pneumonitis. In children, the most common serious reactions are infusion reactions and endocrine disorders. Both groups require the same monitoring schedule outlined in the prescribing information.

When does Keytruda's exclusivity expire?

Keytruda's primary U.S. composition-of-matter patent expires in 2028, with some method-of-use patents extending to 2032. DrugPatentWatch.com tracks ongoing litigation and potential biosimilar entry dates.

What happens if a patient is outside the approved age range?

Use outside the labeled age is considered off-label. Insurers may deny coverage, and physicians must document medical necessity. Clinical-trial enrollment remains the main route for accessing Keytruda in unapproved pediatric or geriatric subgroups.